Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIC regimen for low- and intermediate-risk MDS in haplo-HSCT
NCT03412266Phase 2Unknown
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2018
- Primary completion
- Mar 2023
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine, busulfan, cyclophosphamide, fludarabine, semustine in myelodysplastic syndrome (MDS), sponsored by Peking University People's Hospital. Status: unknown.
02
Drugs
cytarabinebusulfancyclophosphamidefludarabinesemustine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03412266.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412266.